Boehringer Ingelheim, Evotec band with diagnostics player to tackle 'superbugs' through joint venture
Having offered financial support to companies developing antibiotics and fighting antimicrobial resistance, Boehringer Ingelheim is launching its own.
The German pharma is teaming up with Evotec — the drug discovery and development player with whom it already has a long-running R&D alliance in other areas — and French diagnostic company bioMérieux to start a joint venture that will create both next-gen antimicrobials and diagnostics to tackle infectious diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.